Skip to main content
RFAI
NASDAQ Real Estate & Construction

RF Acquisition Corp II Sets August 12 Vote on Six-Month SPAC Deadline Extension to February 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Real Estate
Sentiment info
Neutral
Importance info
8
Price
$11.07
Mkt Cap
$92.365M
52W Low
$10.17
52W High
$11.435
52W Position info
8.8% above low
Off High info
3.2% below high
Rel. Volume
Market data snapshot near publication time

RFAI is trading near its 52-week low of $10.17 (8.8% above the low).

Summary

RF Acquisition Corp II has filed its definitive proxy for an August 12 shareholder vote to extend its SPAC deadline by six months to February 2027, buying time to close its pending merger with Nanyang Biologics. The trust account holds ~$53.5 million, and the business combination vote is slated for August 19.


Key Events · Corporate Governance and Compliance · RFAI

  • Extension Vote Set for August 12

    Shareholders will vote on a six-month extension of the business combination deadline from August 15, 2026 to February 15, 2027, with the meeting held virtually.

  • Trust Account Holds ~$53.5M

    As of the June 25 record date, the trust account balance was approximately $53.5 million, implying a redemption price of about $11.07 per public share — slightly above the recent trading price of $11.03.

  • Business Combination Vote Expected August 19

    The separate meeting to approve the merger with Nanyang Biologics is expected one week after the extension vote, giving shareholders a narrow window to decide on redemption.

  • High Voting Thresholds Require Broad Support

    The extension amendment needs 55.6% of public shares to pass (in addition to the sponsor's 39.1% stake), while the trust agreement amendment and adjournment proposal each need 26.8%.


Analysis · RFAI · Real Estate & Construction

RF Acquisition Corp II is asking shareholders to approve a six-month extension of its business combination deadline from August 15, 2026 to February 15, 2027, with the vote set for August 12. The company has a pending merger with Nanyang Biologics but needs more time to clear SEC and Nasdaq approvals. The definitive proxy reveals a trust account of roughly $53.5 million, implying a redemption price of about $11.07 per share — slightly above the recent trading price. The sponsor and insiders, who hold 39.1% of the vote, support the extension. If the extension fails and the deal isn't done by August 15, the company will liquidate and return the trust funds to public shareholders. The separate business combination vote is expected just one week later, on August 19, giving shareholders a tight window to decide on redemption.

At the time of this filing, RFAI was trading at $11.07 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $92.4M. The 52-week trading range was $10.17 to $11.44. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RFAI - Latest Insights

RFAI
Jul 21, 2026, 4:50 PM EDT
Filing Type: PRE 14A
Importance Score:
8
RFAI
May 07, 2026, 4:32 PM EDT
Source: Wiseek News
Importance Score:
8
RFAI
May 07, 2026, 4:30 PM EDT
Filing Type: 10-Q
Importance Score:
9
RFAI
Mar 19, 2026, 5:07 PM EDT
Filing Type: F-4
Importance Score:
9
RFAI
Feb 11, 2026, 4:15 PM EST
Filing Type: 10-K
Importance Score:
9